When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

Opinion
Video

Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • In your experience, how can physicians and caregivers both support patients in navigating a therapy change? Which resources can best help support patients during a treatment transition?
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.